Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25339589 | 1.00 | LMNA (0.51) | LMNARIPK1CHRM3POLBALDH1A1 | |
| SCHEMBL25339600 | 1.00 | LMNA (0.51) | LMNARIPK1CHRM3POLBALDH1A1 | |
| SCHEMBL30057739 | 0.83 | GPR119 (0.48) | LMNARIPK1CHRM3 | |
| SCHEMBL25341028 | 0.83 | GPR119 (0.48) | LMNARIPK1CHRM3 | |
| SCHEMBL25341026 | 0.83 | GPR119 (0.48) | LMNARIPK1CHRM3 | |
| SCHEMBL25341031 | 0.83 | GPR119 (0.48) | LMNARIPK1CHRM3 | |
| SCHEMBL7085987 | 0.77 | ALDH1A1 (0.55) | LMNACHRM3ALDH1A1KEAP1NFE2L2 | |
| SCHEMBL22092815 | 0.76 | RIPK1 (0.36) | LMNARIPK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL22090116 | 0.76 | RIPK1 (0.36) | LMNARIPK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL21330372 | 0.75 | LMNA (0.74) | LMNARIPK1ALDH1A1KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174710-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR SYNTHESIS | WAVE LIFE SCIENCES LTD. (SG) | 2024-05-30 | — | — | US | disclosed |
| US-11718638-B2 | Compounds, compositions and methods for synthesis | WAVE LIFE SCIENCES LTD. (SG) | 2023-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718638-B2 | Compounds, compositions and methods for synthesis | ALKBH1, DUT, RNGTT | LMNA 434/4885RIPK1 4465/4885CHRM3 3179/4885 |
| US-20240174710-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR SYNTHESIS | ALKBH1, DUT, RNGTT | LMNA 434/4885RIPK1 4465/4885CHRM3 3179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.